[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
3. Shvartsbeyn M, Edelman MJ: Pemetrexed-induced typhlitis in non-small cell lung cancer. J Thorac Oncol; 2008 Oct;3(10):1188-90
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed-induced typhlitis in non-small cell lung cancer.
  • Food and Drug Administration-approved as a second line, single-agent treatment of recurrent metastatic non-small cell lung cancer.
  • In the premetrexed clinical trial database of 1327 patients, various types of colitis were reported by a total of nine patients (0.6%).
  • Typhilitis is a gastrointestinal complication of chemotherapy, which presents as fever and abdominal pain.
  • The diagnosis is supported by the findings of bowel wall thickening on computed tomographic imaging.
  • Typhilitis is usually seen in the setting of severe chemotherapy-induced neutropenia for acute leukemia.
  • Nevertheless, it is increasingly recognized as a complication of therapy in solid tumors.
  • We present the first documented case of typhilitis after treatment with pemetrexed and successful therapy with supportive treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / adverse effects. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Typhlitis / chemically induced
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / complications. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adult. Female. Humans. Pemetrexed. Thymidylate Synthase / antagonists & inhibitors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827618.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


Advertisement
4. Suenaga M, Mizunuma N, Chin K, Matsusaka S, Shinozaki E, Oya M, Ueno M, Yamaguchi T, Muto T, Konishi F, Hatake K: Chemotherapy for small-bowel Adenocarcinoma at a single institution. Surg Today; 2009;39(1):27-31
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for small-bowel Adenocarcinoma at a single institution.
  • PURPOSE: Small-bowel adenocarcinoma (SBA) is rare.
  • No standard chemotherapy for this type of cancer has yet been established.
  • At Cancer Institute Hospital (CIH), the chemotherapy regimen used for colorectal cancer is initially used for patients with SBA, followed by that used for gastric cancer.
  • METHODS: Patients with advanced or recurrent SBA who had been treated with chemotherapy in CIH were retrospectively analyzed.
  • The first-line treatments were fluoropyrimidines used alone or in combination with other drugs, such as 5-fluorouracil plus leucovorin (FL), UFT-E, or TS-1.
  • The second-line treatment was irinotecan (CPT-11) monotherapy.
  • Disease control was seen in five patients (50%) with the first-line chemotherapy and in three (43%) with the second-line.
  • The median overall survival time was 12 months (range 3-39).
  • The treatments were generally tolerated.
  • CONCLUSIONS: Fluoropyrimidines as the first-line and CPT-11 as the second-line chemotherapy yielded low response, although the adverse effects were mild.
  • The FOLFOX and FOLFIRI regimens such as those used for metastatic colorectal cancer are potential alternative strategies.
  • Extensive trials are needed to develop standard chemotherapy with new drugs.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Disease Progression. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Intestine, Small / diagnostic imaging. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Vitamin B Complex / administration & dosage. Vitamin B Complex / adverse effects

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] Am J Surg. 1978 Apr;135(4):601-3 [637208.001]
  • [Cites] Am J Surg. 1987 Apr;153(4):350-4 [3565678.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Am J Surg. 1986 Jun;151(6):654-8 [2424326.001]
  • [Cites] Surg Today. 1997;27(1):60-3 [9035302.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):116-28 [3285475.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):316-22 [15333683.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):396-9 [7425215.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • [Cites] Ann Surg Oncol. 1994 Jul;1(4):290-5 [7850527.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • (PMID = 19132464.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0H43101T0J / irinotecan; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Sawada T, Nishimura M, Hirose K: [Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy]. Gan To Kagaku Ryoho; 2005 Jul;32(7):1059-61
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].
  • A 77-year-old woman underwent an ileocecal resection and a partial resection of the small intestine for cecal cancer.
  • However, ileus caused by a recurrence in the small intestine was detected two years and four months postoperatively, so an ileal resection was performed.
  • Furthermore, metastases to the lungs, lymph nodes, and peritoneum were detected, and CPT-11-based chemotherapy was administered.
  • The patient was initially treated by combination therapy with a small dose of CPT-11 and CDDP.
  • The combination drugs were changed to MMC, 5'-DFUR, etc. while the appearance of adverse reactions was monitored.
  • Three years of continuous treatment served to prevent the proliferation of tumors.
  • At present, TS-1 chemotherapy is ongoing.
  • The results suggest that CPT-11-based chemotherapy can be continued by changing the combination of concomitant drugs while monitoring adverse reactions.
  • It thus may be an effective regimen for advanced and recurrent large bowel cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Floxuridine / administration & dosage. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Mitomycin / administration & dosage. Peritoneal Neoplasms / secondary. Survivors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044974.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; V1JK16Y2JP / doxifluridine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Fu DL, Yang F, Maskay A, Long J, Jin C, Yu XJ, Xu J, Zhou ZW, Ni QX: Primary intestinal malignant fibrous histiocytoma: two case reports. World J Gastroenterol; 2007 Feb 28;13(8):1299-302
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intestinal malignant fibrous histiocytoma: two case reports.
  • Malignant fibrous histiocytoma (MFH) occurs most commonly in the extremities and trunk, but rarely in the intestine.
  • Here we report two cases of primary intestinal MFH.
  • The first case was a 70-year old man admitted for recurrent right lower quadrant abdominal pain.
  • The second case was a 43-year old man with intussusceptions of the small intestine.
  • An emergent laparotomy revealed 4 pedunculated masses in the small bowel and a partial resection of the small intestine was performed.
  • Though the symptoms were not typical, based on histological and immunohistochemical studies, the patients were diagnosed as MFH of the intestine.
  • They were not treated with chemotherapy or radiotherapy and both died within 3 mo.
  • MFH of the intestine is an extremely rare neoplasm with an aggressive biological behavior.
  • Complete surgical excision is preferred, adjuvant chemotherapy or radiotherapy may be advisable.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Intestinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Cecum / pathology. Fatal Outcome. Humans. Intestine, Small / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Burns. 2000 May;26(3):305-10 [10741601.001]
  • [Cites] Surg Today. 2005;35(4):323-7 [15815852.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Skeletal Radiol. 2003 Nov;32(11):613-8 [14517697.001]
  • [Cites] Dig Dis Sci. 2004 Aug;49(7-8):1156-60 [15387338.001]
  • [Cites] Burns. 2004 Nov;30(7):742-5 [15475153.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Exp Hematol. 1993 Sep;21(10):1342-52 [7689482.001]
  • [Cites] Gastroenterol Jpn. 1993 Aug;28(4):554-63 [7690726.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):91-6 [8548744.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [Cites] Pathol Int. 1997 Oct;47(10):718-24 [9361108.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jan 15;100(2):134-42 [9428357.001]
  • [Cites] Surg Today. 1999;29(2):160-4 [10030742.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):447-8 [10419723.001]
  • [Cites] APMIS. 1999 Sep;107(9):837-42 [10519319.001]
  • [Cites] Mt Sinai J Med. 2005 Jan;72(1):50-2 [15682264.001]
  • [Cites] Surg Today. 2001;31(3):242-5 [11318129.001]
  • (PMID = 17451221.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4147015
  •  go-up   go-down


7. Gibson MK, Holcroft CA, Kvols LK, Haller D: Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist; 2005 Feb;10(2):132-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
  • BACKGROUND: Small bowel adenocarcinoma is a rare gastrointestinal malignancy that is treated primarily with surgery.
  • Response rates to palliative combination chemotherapy are low, and the median duration of survival for metastatic disease is less than 1 year.
  • This study aimed to document the response rate and survival time for patients with advanced small bowel adenocarcinoma who were not surgically curable and were treated with a regimen of 5-fluorouracil (5-FU), mitomycin C (Mutamycin; Bristol-Myers Squibb; Princeton, NJ), and doxorubicin (Adriamycin; Bedford Laboratories; Bedford, OH), the FAM regimen.
  • Between November, 1983 and December, 1985, 39 patients with advanced or recurrent disease were enrolled.
  • Chemotherapy was given as follows: 5-FU, 600 mg/m(2) on days 1, 8, 29 and 36; mitomycin C, 10 mg/m(2) on day 1; and doxorubicin, 30 mg/m(2) on days 1 and 29.
  • Prior chemotherapy was allowed.
  • Survival time and time to progression were evaluated by the method of Kaplan and Meier, and these outcomes were stratified by clinical and laboratory covariates.
  • The median survival time was 8 months.
  • CONCLUSIONS: The FAM regimen was active and tolerable for patients with advanced small bowel adenocarcinoma; however, the results were no better than those seen with other chemotherapy combinations.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709215.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Mohiuddin M, Marks G, Marks J: Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer; 2002 Sep 1;95(5):1144-50
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of reirradiation for patients with recurrent rectal carcinoma.
  • BACKGROUND: The current study was conducted to assess the long-term results of reirradiation in patients with recurrent rectal carcinoma.
  • METHODS: One hundred and three patients with recurrent adenocarcinoma of the rectum underwent reirradiation with concurrent 5-fluorouracil-based chemotherapy.
  • The median time from initial treatment to recurrence was 19 months.
  • Irradiation techniques consisted of two lateral fields with/without a posterior pelvic field to include recurrent tumor with a margin of 2-4 cm only.
  • Treatment was generally well tolerated.
  • Fifteen patients required a treatment break and early termination of treatment for Grade 3 and higher diarrhea, moist desquamation, or mucositis.
  • Late complications were seen in 22 patients, including persistent severe diarrhea in 18 patients with 10 patients requiring long-term parental support, small bowel obstruction was seen in 15 patients, fistula formation in 4 patients, and coloanal stricture in 2 patients.
  • CONCLUSIONS: In patients with recurrent rectal carcinoma, high doses of reirradiation can be delivered with acceptable risks without prohibitive long-term side effects.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diarrhea / etiology. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Intestinal Mucosa / radiation effects. Male. Middle Aged. Salvage Therapy. Stomatitis / etiology. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12209702.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Gücer F, Oz-Puyan F, Yilmaz O, Mülayim N, Balkanli-Kaplan P, Yüce MA: Endometrial carcinoma with laparotomy wound recurrence: complete remission following surgery and chemotherapy consisting of paclitaxel and carboplatin. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1195-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma with laparotomy wound recurrence: complete remission following surgery and chemotherapy consisting of paclitaxel and carboplatin.
  • We present a patient with surgical stage I endometrial cancer who experienced laparotomy wound recurrence 4 years after primary treatment.
  • She was treated successfully by complete surgical resection of recurrent tumors and chemotherapy.
  • A 62-year-old white female with laparotomy wound recurrence of endometrial carcinoma with small-bowel involvement and concomitant subcutaneous metastasis in the abdominal wall underwent complete surgical resection of metastatic tumors followed by six cycles of chemotherapy consisting of paclitaxel (175 mg/m2) and carboplatin (area under the curve 5).
  • Endometrial carcinoma with laparotomy wound recurrences, especially those with concomitant metastases, can be successfully treated by complete surgical resection followed by chemotherapy consisting of paclitaxel and carboplatin.
  • [MeSH-major] Carcinoma, Endometrioid / therapy. Endometrial Neoplasms / therapy. Intestinal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Paclitaxel / administration & dosage. Remission Induction. Surgical Procedures, Operative. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343212.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Myerson RJ, Valentini V, Birnbaum EH, Cellini N, Coco C, Fleshman JW, Gambacorta MA, Genovesi D, Kodner IJ, Picus J, Ratkin GA, Read TE: A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1299-308
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
  • BACKGROUND: Improving the response to preoperative therapy may increase the likelihood of successful resection of locally advanced rectal cancers.
  • Historically, the pathologic complete response (pCR) rate has been < approximately 10% with preoperative radiation therapy alone and < approximately 20% with concurrent chemotherapy and radiation therapy.
  • METHODS AND MATERIALS: Thirty-seven patients were enrolled on a prospective Phase I/II protocol conducted jointly at Washington University, St. Louis and the Catholic University of the Sacred Heart, Rome evaluating a three-dimensionally (3D) planned boost as part of the preoperative treatment of patients with unresectable or recurrent rectal cancer.
  • Preoperative treatment consisted of 4500 cGy in 25 fractions over 5 weeks to the pelvis, with a 3D planned 90 cGy per fraction boost delivered once or twice a week concurrently (no time delay) with the pelvic radiation.
  • The boost treatment was twice a week (total boost dose 900 cGy) if small bowel could be excluded from the boost volume, otherwise the boost was delivered once a week (total boost dose 450 cGy).
  • The most important factor for pCR was tumor volume: small lesions with planning target volume (PTV) < 200 cc showed a 50% pCR rate (p = 0.02).
  • There were no treatment associated fatalities.
  • Nine of the 37 patients (24%) experienced Grade 3 or 4 toxicities (usually proctitis) during preoperative treatment.
  • The most important factors for small bowel toxicity (acute or late) were small bowel volume (> or = 150 cc at doses exceeding 4000 cGy) and large tumor (PTV > or = 800 cc).
  • CONCLUSION: 3D planned boost therapy is feasible.
  • In addition to permitting the use of nonaxial beams for improved dose distributions, 3D planning provides tumor and normal tissue dose-volume information that is important in interpreting outcome.
  • Every effort should be made to limit the treated small bowel to less than 150 cc.
  • Tumor size is the most important predictor of response, with small lesions of PTV < 200 cc most likely to develop complete responses.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Imaging, Three-Dimensional. Neoadjuvant Therapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Adjuvant. Radiotherapy, High-Energy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Intestine, Small / radiation effects. Male. Middle Aged. Missouri / epidemiology. Neoplasm Invasiveness. Pelvis / radiation effects. Proctitis / epidemiology. Proctitis / etiology. Prospective Studies. Radiation Injuries / epidemiology. Radiation Injuries / etiology. Remission Induction. Rome / epidemiology. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483342.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Omura K: [Specialized nutrition support for the patients with advanced or recurrent carcinoma of the gastrointestinal tract]. Nihon Geka Gakkai Zasshi; 2004 Feb;105(2):228-32
Hazardous Substances Data Bank. CYANOCOBALAMIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Specialized nutrition support for the patients with advanced or recurrent carcinoma of the gastrointestinal tract].
  • Various nutritional disorders can occur in patients with advanced or recurrent carcinoma of the gastrointestinal tract due to the disease itself or the absence of the organs after surgery.
  • Routine parenteral nutrition for cancer patients who undergo chemotherapy results in no benefit and troublesome complications such as catheter sepsis.
  • Patients with advanced or recurrent carcinoma of the gastrointestinal tract are likely to be deficient in folate and/or vitamin B12 for various reasons.
  • This phenomenon should be avoided when 5-fluorouracil is used with reduced folate in cancer chemotherapy.
  • The indications for specialized nutritional support for patients with advanced or recurrent carcinoma of the gastrointestinal tract are the same as for malnourished patients without cancer.
  • The initial dose and formula of nutrition for cancer patients with malnutrition and various metabolic disorders should be calculated to avoid overloading.
  • The placement of a central venous catheter to prevent the toxicity of chemotherapy or for venous access is contraindicated.
  • If any bowel obstruction occurs in the small intestine and/or colon, it is necessary to discuss the efficacy of surgery to resolve the obstruction.
  • [MeSH-major] Gastrointestinal Neoplasms / drug therapy. Nutritional Support / methods

  • MedlinePlus Health Information. consumer health - Nutritional Support.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15027166.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  • [Number-of-references] 12
  •  go-up   go-down


14. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 24 patients enrolled: 13 M, 11F; median age 62 (32-77); median number of prior cytotoxic chemotherapy regimens 1 (0-3; 75% with prior RT).
  • At DL1, 3 patients were inevaluable (1 withdrawal of consent prior to treatment, 1 disease progression during cycle 1, 1 recurrent diverticulitis during cycle 1) and were replaced.
  • At DL2, one patient experienced grade 3 small bowel obstruction of uncertain etiology, and the dose level was expanded to 6 evaluable patients without additional DLT.
  • Minor response seen in pulmonary carcinoid (n = 1); prolonged SD ≥ 6 cycles seen in pulmonary carcinoid (n=2), basal cell carcinoma (n=1), and esthesioneuroblastoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Konner JA, Grabon D, Pezzulli S, Iasonos A, Sabbatini P, Hensley M, Bell-McGuinn K, Tew W, Spriggs D, Aghajanian C: A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer.
  • : 5539 Background: IP cisplatin (Cis) plus IV/IP paclitaxel (Tax) is a standard therapy for optimally debulked ovarian cancer.
  • Activity of Bev in recurrent ovarian cancer has been reported in phase II trials.
  • In this study IP Cis and IV/IP Tax are combined with IV Bev as front-line therapy.
  • METHODS: Patients with optimal (<1 cm residual), FIGO stage II or III, epithelial ovarian, fallopian tube, or peritoneal cancer, acceptable organ function, and KPS ≥ 70% are eligible.
  • Patients receive 6 cycles of chemotherapy plus Bev: Tax 135 mg/m<sup>2</sup> IV over 3 hours on Day 1, Cis 75 mg/m<sup>2</sup> IP on Day 2, Tax 60 mg/m<sup>2</sup> IP on Day 8, Bev 15 mg/kg IV on Day 1 (starting cycle 2).
  • Bev is continued every 3 weeks for 17 treatments after chemotherapy is complete.
  • The primary endpoint is safety and tolerability, determined by whether at least 60% of patients complete the prescribed 6 cycles of cytotoxic chemotherapy without unacceptable toxicity.
  • RESULTS: Thirty-nine women [median age 56 (40-69)] have been treated on study: 26 (67%) completed 6 IV/IP cycles; 5 (13%) are receiving ongoing IV/IP treatment; 4 (10%) experienced IP port malfunction (3 finished 5 IV/IP cycles, 1 came off study for port revision); 3 (8%) switched from IP Cis to IV carboplatin due to grade 3 nephrotoxicity in cycle 1 (n = 2) or grade 3 hypertension in cycle 6 (n = 1); and 1 (2.5%) patient died following rectosigmoid anastomotic dehiscence during cycle 4.
  • Grade 3/4 treatment-related toxicities include hypertension (10%), vasovagal events (10%), neutropenia (26%), nausea/vomiting (10%), and hypomagnesemia (8%).
  • There were 3 occurrences of grade 3 abdominal pain (8%); and 3 adhesion-related grade 3 small bowel obstructions (8%), during cycles 3, 9, and 15, respectively.
  • Bev may increase the risk of small bowel obstruction/perforation in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962485.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA: High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer; 2008 Jul;47(7):591-603
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss.
  • Carcinoid tumors of the small intestine are characterized by an indolent clinical course, secretion of neuropeptides, and resistance to standard cytotoxic chemotherapy.
  • To evaluate the molecular events underlying carcinoid tumorigenesis, we used high-resolution arrays of single nucleotide polymorphisms to study chromosomal gains and losses in 24 primary and metastatic small bowel carcinoid tumors derived from 18 patients.
  • The amplitude of observed gains was modest in comparison to those reported in some other tumor types.
  • One focal region of recurrent gain on 14q mapped to the locus of the gene encoding the antiapoptotic protein DAD1, and immunohistochemical staining confirmed DAD1 protein expression in tumor samples.
  • This detailed study of an uncommon neoplasm provides a basis to investigate putative oncogenes and tumor suppressor genes in intestinal carcinoid tumors.
  • [MeSH-major] Chromosome Aberrations. Intestinal Neoplasms / genetics. Intestine, Small. Liver Neoplasms / genetics. Malignant Carcinoid Syndrome / genetics. Neoplasm Recurrence, Local / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18383209.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / DAD1 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


17. Okubo K, Yoshioka S, Asukai K, Hata T, Nakanishi M, Maekawa T, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Yano K, Fujimoto T: [A case report of primary adenocarcinoma of small intestine]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2792-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary adenocarcinoma of small intestine].
  • This is an account of a case of primary adenocarcinoma of the small intestine with peritoneal dissemination successfully treated with chemotherapy.
  • Abdominal computerized tomography revealed a bowel obstruction with tumor and the remarkable small bowel dilation of oral side of tumor.
  • Peritoneal dissemination was recognized around the ileocecal region, so ileum partial resection was performed for the primary cancer lesion and dissemination region.
  • The peritoneal dissemination consisted of metastatic adenocarcinoma from small intestine.
  • After an operation, internal use of S-1 was performed as adjuvant chemotherapy.
  • But a recurrent lesion at the ovarium was detected 6 months after surgery.
  • For lung metastasis, the combination chemotherapy with mFOLFOX6 + bevacizumab was administered.
  • Primary small intestinal adenocarcinoma is a rare disease, and it is often diagnosed as advanced cancer because of few characteristic symptoms.
  • So carcinoma of the small intestine usually has a poor prognosis.
  • [MeSH-major] Adenocarcinoma / therapy. Intestinal Neoplasms / therapy
  • [MeSH-minor] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bevacizumab. Combined Modality Therapy. Drug Combinations. Female. Fluorouracil / administration & dosage. Humans. Ileal Neoplasms / drug therapy. Leucovorin / administration & dosage. Lymphatic Metastasis. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovarian Neoplasms / secondary. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224715.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Organoplatinum Compounds; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 2S9ZZM9Q9V / Bevacizumab; 5VT6420TIG / Oxonic Acid; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


18. Palermo JA, Richards F, Lohman KK, Lovelace JV, Atkinson J, Case LD, White DR, Blackstock AW: Phase II trial of adjuvant radiation and intraperitoneal 5-fluorouracil for locally advanced colon cancer: results with 10-year follow-up. Int J Radiat Oncol Biol Phys; 2000 Jun 1;47(3):725-33
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of adjuvant radiation and intraperitoneal 5-fluorouracil for locally advanced colon cancer: results with 10-year follow-up.
  • PURPOSE: To determine the toxicity, disease-free survival, and overall survival for patients with Modified Astler-Coller (MAC) B2-3 or C1-3 colon cancer receiving adjuvant radiation and sequential intraperitoneal 5-fluorouracil (5-FU).
  • The radiation was delivered to the tumor bed and para-aortic lymph nodes in two split-courses of 22.5 Gy, alternating with the first two cycles of chemotherapy.
  • RESULTS: The therapy was well tolerated with 4 patients experiencing Grade 3 peritonitis.
  • Four patients developed small bowel obstruction requiring surgery; in each instance, recurrent tumor was found at the time of laparotomy.
  • CONCLUSIONS: Sequential intraperitoneal 5-FU and tumor-bed/para-aortic irradiation is tolerable in patients with resected colon cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / radiotherapy. Fluorouracil / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infusions, Parenteral. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Peritonitis / etiology. Radiotherapy, Adjuvant. Survival Rate. Treatment Failure

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10837957.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Sugae T, Yaguchi T, Kajikawa M, Nakayama S, Takase T, Inokawa Y, Tsushima Y, Watanabe T, Harada A: [A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1969-71
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX].
  • This is an account of a case of primary adenocarcinoma of the small intestine successfully treated with chemotherapy.
  • Abdominal computerized tomography revealed bowel obstruction, and this was found at surgery to be due to a tumor at the jejunum 100 cm distal from the Treitz ligament.
  • Although adjuvant chemotherapy with doxifluridine 800 mg/day was given, a recurrent lesion at the abdominal wall was detected 19 months after surgery.
  • It was not long before another recurrence developed at the abdominal wall with a subsequent rise in tumor markers. mFOLFOX6 (oxaliplatin 85 mg/m2, levofolinate calcium 200 mg/m2, 5-FU 400/2,400 mg/m2) was given, and the patient responded.
  • Primary small intestinal adenocarcinoma is a rare disease with a dismal prognosis.
  • Due to rarity of the disease, clinical trials have not been performed, and little is known about the effect of chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / pathology. Intestine, Small / drug effects
  • [MeSH-minor] Carcinoembryonic Antigen / blood. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / therapeutic use. Tomography, X-Ray Computed. Treatment Failure

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011354.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


22. Nasu K, Umekita N, Noda K, Tanaka S, Maeshiro T, Miyamoto S, Inoue S, Arai K: [A case of recurrent colon cancer patient who gained a long-term survival by repeated and aggressive surgical resection]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2150-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent colon cancer patient who gained a long-term survival by repeated and aggressive surgical resection].
  • We performed right hemicolectomy with liver S7 partial excision (a postoperative diagnosis of the hepatic lesion, adenoma) for ascending colon carcinoma of type 2 with hepatic metastasis.
  • Postoperative diagnosis was ss, n2, ly2, v2, Stage IIIb, based on the Japanese classification of colon cancer.
  • Twelve months after the first operation, she was developed intestinal atresia by an abdominal wall recurrence, and we performed the operation of abdominal wall mass resection with a partial resection of small bowel.
  • Afterwards she developed a recurrence three times in the abdominal wall or intra-abdominal lymph nodes during the next 1 year and six months, and we performed a local excision each time.
  • The pathological findings in reoperations were all metastasis from ascending colon carcinoma of primary operation.
  • After the final operation, we did not perform chemotherapy because the patient wished not to have it.
  • Recently, the therapy for recurrent colon cancer has been shifted to more effective chemotherapy such as FOLFOX or FOLFIRI regimen, and a surgical resection is becoming rare.
  • However, we experienced a case of recurrent colon cancer treated with four aggressive surgical resections that was beneficial for a long-term survival.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymphatic Metastasis. Middle Aged. Positron-Emission Tomography. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106553.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani AB, Heimann R: Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys; 2004 Jun 1;59(2):445-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.
  • METHODS AND MATERIALS: Twenty-five patients with pancreatic and bile duct cancer were treated with IMRT.
  • Eight patients had resected tumors, and 17 had unresectable primary (n = 14) or recurrent (n = 3) tumors.
  • Six patients underwent treatment planning with conventional three-dimensional four-field techniques for dosimetric comparison with IMRT.
  • RESULTS: Compared with conventional RT, IMRT reduced the mean dose to the liver, kidneys, stomach, and small bowel.
  • At a median follow-up of 10.2 months, no resected patients had local failure, and only 1 of 10 assessable patients with unresectable cancer had local progression.
  • CONCLUSION: In this hypothesis-generating analysis, the acute and chronic toxicity profile with IMRT in the treatment of pancreatic and bile duct cancer was encouraging.
  • Distant failure remains a major obstacle in pancreatic cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / therapeutic use. Humans. Imaging, Three-Dimensional / methods. Middle Aged. Neuroectodermal Tumors / drug therapy. Neuroectodermal Tumors / radiotherapy. Radiation Injuries / etiology. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15145161.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Goodman KA, Wolden SL, LaQuaglia MP, Alektiar K, D'Souza D, Zelefsky MJ: Intraoperative high-dose-rate brachytherapy for pediatric solid tumors: a 10-year experience. Brachytherapy; 2003;2(3):139-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-five patients (53%) were treated for recurrent disease and 24 (36%) had documented metastatic disease.
  • The IOHDR dose was prescribed to a depth of 0.5 cm from the surface of a multichannel tissue-equivalent applicator.
  • The median prescription dose was 12 Gy (range, 4-15 Gy).
  • Late events that occurred in or near the IOHDR treatment site included small bowel obstruction, broncho-esophageal fistula, and bone growth retardation.
  • CONCLUSIONS: IOHDR is emerging as an integral part of multimodality therapy for pediatric solid tumors as an adjunct to EBRT for local control.
  • Subacute toxicities occurred rarely and may be related to the combination of extensive surgery, EBRT, and multi-agent chemotherapy in this population.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Intraoperative Period. Male. Morbidity. Radiotherapy Dosage. Retrospective Studies. Sarcoma / drug therapy. Sarcoma / radiotherapy. Sarcoma / surgery. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15062136.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Cerrotta A, Gardan G, Cavina R, Raspagliesi F, Stefanon B, Garassino I, Musumeci R, Tana S, De Palo G: Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. Eur J Gynaecol Oncol; 2002;23(2):115-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose.
  • OBJECTIVE: This study included patients with inoperable primary or recurrent cervical cancer whose treatment plan called for exclusive radiotherapy.
  • In new cases, radiotherapy was conventionally administered: 50.4 Gy/28 fractions by external beam (whole pelvis) followed by intracavitary cesium or reduced transcutaneous field.
  • Five patients (3 treated with 40 mg/m2 and 2 with 60 mg/m2) experienced grade 3 small bowel toxicity, one patient treated with 40 mg/m2 grade 3 bladder toxicity and one patient treated with 60 mg/m2 had grade 4 mucositis.
  • Out of 12 CR patients at the end of treatment, ten maintain complete local remission for a median follow-up of 47 months but two have developed distant metastases.
  • CONCLUSION: The results confirm that this approach is feasible and suggest the use of paclitaxel as radiosensitizer in locally advanced cervical cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Paclitaxel / therapeutic use. Radiation-Sensitizing Agents / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Pilot Projects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12013105.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Müller H, Nakchbandi V: Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases. Eur J Surg Oncol; 2004 Jun;30(5):573-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases.
  • Due to its rarity, there is no agreement on the best treatment strategy in women with metastasized MMMT.
  • METHODS: Six women (mean age 59 years) with metastasized MMMT defined to the peritoneal cavity have been treated by cytoreductive surgery plus hyperthermic peritoneal perfusion plus postoperative adjuvant chemotherapy.
  • All patients have been pre-treated by surgery for primary tumour and one by systemic chemotherapy.
  • As adjuvant treatment CDDP 40 mg/m2/dl, Mitomycin 7 mg/md2/dl and Ifosfamid 100 mg/kg 24 h/dl was applicated via intraaortic catheter three times with a treatment free interval of 3 weeks.
  • The postoperative course was uneventful in all cases except for one where a spontaneous small bowel perforation and prolonged gall secretion had to be treated by re-operation.
  • Four patients are without evidence of disease after 2, 4, 14 and 19 months, whereas one patient developed liver metastases after 9 months still treated by systemic chemotherapy.
  • CONCLUSION: Complete cytoreduction plus hyperthermic peritoneal perfusion plus adjuvant chemotherapy seems to be an effective treatment for recurrent or metastasized MMMT.
  • Further studies have to define the value of this new treatment strategy for this rare tumour entity.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mixed Tumor, Malignant / secondary. Mixed Tumor, Malignant / therapy. Mixed Tumor, Mesodermal / secondary. Mixed Tumor, Mesodermal / therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Germany. Humans. Ifosfamide / administration & dosage. Laparotomy. Liver / pathology. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Peritoneal Cavity / pathology. Treatment Outcome. Women's Health

  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2005 Feb;31(1):111-2 [15642436.001]
  • (PMID = 15135489.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 50SG953SK6 / Mitomycin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


27. Tönjes A, Karger S, Koch CA, Paschke R, Tannapfel A, Stumvoll M, Fuhrer D: Impaired enteral levothyroxine absorption in hypothyroidism refractory to oral therapy after thyroid ablation for papillary thyroid cancer: case report and kinetic studies. Thyroid; 2006 Oct;16(10):1047-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired enteral levothyroxine absorption in hypothyroidism refractory to oral therapy after thyroid ablation for papillary thyroid cancer: case report and kinetic studies.
  • We present a 49-year-old patient suffering from hypothyroidism (thyrotropin [TSH], 20-80 mU/L) refractory to oral levothyroxine (LT(4)) substitution after total thyroidectomy and radioiodine therapy for papillary thyroid cancer.
  • Extensive, repetitive work-up excluded small bowel, liver, and pancreatic disease and drug interactions.
  • Supervised absorption tests of several LT(4) preparations in increasing dosages (250-1500 microg/d) confirmed an insufficient rise in serum T(4) levels following oral drug administration.
  • Thus, intravenous LT(4) application (5 times per week) was commenced to restore at least normal range TSH levels.
  • Repetition of absorption tests 1 year later, after a documented period of more than 3 months of stable euthyroidism, showed a considerable improvement of intestinal LT(4) uptake.
  • Of note, at 4-year follow-up there was no evidence of recurrent or metastasized papillary thyroid cancer.
  • The reason for the disturbed intestinal LT(4) absorption in this patient remains unresolved.
  • However, we would like to suggest the possibility of a specific intestinal uptake deficit, which will only become apparent in the case of previous thyroid ablation.
  • [MeSH-major] Carcinoma, Papillary / surgery. Hypothyroidism / drug therapy. Intestinal Absorption. Thyroid Neoplasms / surgery. Thyroxine / pharmacokinetics. Thyroxine / therapeutic use


28. Cho JE, Liu C, Gossner G, Nezhat FR: Laparoscopy and gynecologic oncology. Clin Obstet Gynecol; 2009 Sep;52(3):313-26
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopy was used for a second-look assessment in ovarian cancer patients back in the 1970s.
  • Laparoscopy has multiple benefits in the cancer patients, including image magnification to visualize metastatic or recurrent disease and improved dissection in challenging areas such as the paravesical and pararectal spaces.
  • There is limited bleeding from small vessels because of the pressure from pneumoperitoneum, decreased hospital stay, and rapid recovery.
  • Postoperative chemotherapy or radiation can be initiated earlier, and radiation complications from bowel adhesions are minimized.
  • In this study, the application of laparoscopy in cervical, endometrial, and ovarian cancer will be presented.
  • [MeSH-minor] Algorithms. Brachytherapy / methods. Endometrial Neoplasms / surgery. Female. Humans. Hysterectomy / methods. Lymph Node Excision. Neoplasm Staging. Pelvic Exenteration. Robotics. Second-Look Surgery. Sentinel Lymph Node Biopsy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661747.001).
  • [ISSN] 1532-5520
  • [Journal-full-title] Clinical obstetrics and gynecology
  • [ISO-abbreviation] Clin Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


29. Jingu K, Ariga H, Kaneta T, Takai Y, Takeda K, Katja L, Narazaki K, Metoki T, Fujimoto K, Umezawa R, Ogawa Y, Nemoto K, Koto M, Mitsuya M, Matsufuji N, Takahashi S, Yamada S: Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP. BMC Cancer; 2010;10:127
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP.
  • BACKGROUND: To evaluate the safety of focal dose escalation to regions with standardized uptake value (SUV) >2.0 using intensity-modulated radiation therapy (IMRT) by comparison of radiotherapy plans using dose-volume histograms (DVHs) and normal tissue complication probability (NTCP) for postoperative local recurrent rectal cancer METHODS: First, we performed conventional radiotherapy with 40 Gy/20 fr. (CRT 40 Gy) for 12 patients with postoperative local recurrent rectal cancer, and then we performed FDG-PET/CT radiotherapy planning for those patients.
  • The total boost dose was 20 Gy.
  • We added CRT boost plan to CRT 40 Gy (summed plan 1), IMRT without dose-painting boost plan to CRT 40 Gy (summed plan 2) and IMRT with dose-painting boost plan to CRT 40 Gy (summed plan 3), and we compared those plans using DVHs and NTCP.
  • RESULTS: D(mean) of PTV-PET and that of PTV-CT were 26.5 Gy and 21.3 Gy, respectively.
  • V50 of small bowel PRV in summed plan 1 was significantly higher than those in other plans ((summed plan 1 vs. summed plan 2 vs. summed plan 3: 47.11 +/- 45.33 cm3 vs. 40.63 +/- 39.13 cm3 vs. 41.25 +/- 39.96 cm3 (p < 0.01, respectively)).
  • There were no significant differences in V30, V40, V60, D(mean) or NTCP of small bowel PRV.
  • CONCLUSIONS: FDG-PET-guided IMRT can facilitate focal dose-escalation to regions with SUV above 2.0 for postoperative local recurrent rectal cancer.
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Dose-Response Relationship, Radiation. Drug Combinations. Humans. Oxonic Acid / administration & dosage. Positron-Emission Tomography. Radiotherapy, Intensity-Modulated / methods. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2002 Jan;62(1):51-60 [11830312.001]
  • [Cites] J Nucl Med. 2009 May;50 Suppl 1:43S-54S [19403879.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):339-50 [11872279.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3623-8 [14512393.001]
  • [Cites] Radiology. 2004 Oct;233(1):93-100 [15317953.001]
  • [Cites] Cancer. 1974 Oct;34(4):1278-92 [4424091.001]
  • [Cites] Adv Exp Med Biol. 1984;180:293-300 [6534106.001]
  • [Cites] Radiat Res Suppl. 1985;8:S13-9 [3867079.001]
  • [Cites] Dis Colon Rectum. 1986 Dec;29(12):865-8 [2431843.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):123-35 [2032883.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):137-46 [2032884.001]
  • [Cites] J Nucl Med. 1991 Aug;32(8):1485-90 [1714497.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):199-212 [1727119.001]
  • [Cites] Adv Exp Med Biol. 1994;345:445-50 [8079741.001]
  • [Cites] Strahlenther Onkol. 1995 Feb;171(2):77-86 [7863430.001]
  • [Cites] J Nucl Med. 1995 Sep;36(9):1625-32 [7658223.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):700-8 [8622014.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4509-15 [8813149.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1177-89 [10914907.001]
  • [Cites] J Nucl Med. 2001 Jan;42(1):170-5 [11197971.001]
  • [Cites] J Nucl Med. 2001 Apr;42(4):655-61 [11337556.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):31-9 [8961365.001]
  • [Cites] J Am Coll Surg. 1997 May;184(5):475-80 [9145067.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):285-9 [9226314.001]
  • [Cites] World J Surg. 1997 Sep;21(7):728-32 [9276704.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):427-35 [9457832.001]
  • [Cites] Langenbecks Arch Surg. 1998 Dec;383(6):409-15 [9921940.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):9-15 [15690651.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1385-92 [15817341.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):299-300; author reply 300 [15850948.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):545-53 [15890599.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1169-75 [15793645.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):143-51 [16618577.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:19S-27S [17204717.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:58S-67S [17204721.001]
  • [Cites] Ann Nucl Med. 2007 Feb;21(2):101-7 [17424976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1219-28 [18313529.001]
  • [Cites] Ann Surg. 2009 Feb;249(2):229-35 [19212175.001]
  • [Cites] Tech Coloproctol. 2001 Aug;5(2):97-102 [11862566.001]
  • (PMID = 20374623.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  • [Other-IDs] NLM/ PMC2858110
  •  go-up   go-down


30. Pestieau SR, Jelinek JS, Chang D, Jacquet P, Sugarbaker PH: CT in the selection of patients with abdominal or pelvic sarcoma for reoperative surgery. J Am Coll Surg; 2000 Jun;190(6):700-10
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this clinical situation, further surgical treatments in an attempt to control the disease may be appropriate.
  • STUDY DESIGN: Preoperative abdominal and pelvic CT scans of 33 patients with recurrent sarcoma were reviewed retrospectively.
  • All patients underwent reoperative surgery and, when appropriate, perioperative intraperitoneal chemotherapy.
  • These findings included tumor in the left lower quadrant (p = 0.032), tumor in the pelvis (p = 0.008), and tumor in the distal jejunum (p = 0.032).
  • Two other CT indices that showed a significant difference in survival between the groups were involvement of five abdominopelvic regions or fewer (p = 0.008) and a peritoneal cancer index of 15 or less (p = 0.03).
  • A statistical approach using a tree-structured diagram showed that patients with tumor diameter greater than 5 cm in the pelvis accompanied by tumor involvement of more than one segment of small bowel had a 0% probability of postoperative disease-free survival.
  • CONCLUSIONS: For patients with recurrent sarcoma, selection criteria were generated by a preoperative CT of the abdomen and pelvis.
  • [MeSH-major] Abdominal Neoplasms / radiography. Abdominal Neoplasms / surgery. Patient Selection. Pelvic Neoplasms / radiography. Pelvic Neoplasms / surgery. Sarcoma / radiography. Sarcoma / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10873006.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down






Advertisement